Want to see TSE:HEM full AI Analyst Report?
Top Page
Hemostemix
(HEM)
Select Model
Select Model
Rating:42Neutral
Price Target:
C$0.06
▼(-17.14% Downside)
Action:Reiterated
Date:10/29/26
The score is primarily held down by weak financial performance: no revenue, recurring losses, worsening cash burn, and a stressed balance sheet with negative equity that heightens funding and dilution risk. Technicals add a secondary headwind with price below key longer-term moving averages and negative MACD. Valuation provides little offset due to a non-meaningful negative P/E and no dividend yield data.
Positive Factors
Regenerative medicine platform
Hemostemix is focused on a specialized regenerative-medicine platform rather than a broad, unfocused pipeline. Its patient-derived approach and emphasis on vascular regeneration provide a defined scientific strategy that could support differentiated clinical value if development succeeds.
Negative Factors
Pre-commercial revenue profile
The absence of revenue confirms that Hemostemix remains pre-commercial and has not yet demonstrated product-market monetization. Until a therapy reaches commercialization, the company cannot rely on operating revenue to fund development, making progress dependent on successful clinical and regulatory execution.
Read all positive and negative factors
Positive Factors
Negative Factors
Regenerative medicine platform
Hemostemix is focused on a specialized regenerative-medicine platform rather than a broad, unfocused pipeline. Its patient-derived approach and emphasis on vascular regeneration provide a defined scientific strategy that could support differentiated clinical value if development succeeds.
Read all positive factors
Hemostemix (HEM) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$12.69M
Dividend YieldN/A
Average Volume (3M)29.36K
Price to Earnings (P/E)―
Beta (1Y)0.53
Revenue GrowthN/A
EPS Growth16.04%
CountryCA
Employees12
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.02
Shares Outstanding211,441,440
10 Day Avg. Volume21,412
30 Day Avg. Volume29,360
Financial Highlights & Ratios
PEG Ratio-0.66
Price to Book (P/B)-2.96
Price to Sales (P/S)0.00
P/FCF Ratio-3.24
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.14
Revenue Forecast (FY)N/A
Hemostemix Business Overview & Revenue Model
Company Description
Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, which is in Phase II clinical trial for the treatme...
Hemostemix Financial Statement Overview
Summary
Income Statement
6
Very Negative
Balance Sheet
9
Very Negative
Cash Flow
7
Very Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -33.00 | -46.00 | -100.00 | -223.00 | -495.00 | -1.10K |
| EBITDA | -4.30M | -4.26M | -1.98M | -1.95M | -4.39M | -6.45M |
| Net Income | -4.54M | -4.71M | -2.62M | -2.50M | -5.24M | -6.29M |
Balance Sheet | ||||||
| Total Assets | 257.07K | 846.90K | 991.86K | 313.76K | 465.35K | 563.05K |
| Cash, Cash Equivalents and Short-Term Investments | 196.46K | 741.72K | 705.70K | 155.42K | 135.75K | 219.44K |
| Total Debt | 3.56M | 3.60M | 4.94M | 4.32M | 4.13M | 1.48M |
| Total Liabilities | 6.02M | 5.82M | 8.20M | 7.68M | 7.23M | 5.85M |
| Stockholders Equity | -5.76M | -4.97M | -7.20M | -7.37M | -6.77M | -5.28M |
Cash Flow | ||||||
| Free Cash Flow | -5.27M | -4.53M | -1.90M | -1.42M | -6.10M | -3.48M |
| Operating Cash Flow | -5.27M | -4.53M | -1.90M | -1.42M | -6.10M | -3.48M |
| Investing Cash Flow | -304.00 | -145.88K | 0.00 | 0.00 | 0.00 | 171.12K |
| Financing Cash Flow | 4.73M | 4.66M | 2.45M | 1.44M | 6.02M | 3.27M |
Hemostemix Technical Analysis
Negative
0.07
Price Trends
0.07
Negative
0.06
Negative
0.07
Negative
Market Momentum
>-0.01
Negative
44.22
Neutral
66.67
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:HEM, the sentiment is Negative. The current price of 0.07 is above the 20-day moving average (MA) of 0.06, above the 50-day MA of 0.07, and above the 200-day MA of 0.07, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 44.22 is Neutral, neither overbought nor oversold. The STOCH value of 66.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:HEM.
Hemostemix Peers Comparison
UnderperformOutperform
Sector (55)
TSE:HEM
Hemostemix
0.06
-0.04
-36.84%
TSE:IOT
Innovotech
0.07
-0.17
-71.74%
TSE:BLAB
Britannia Life Sciences Inc
0.07
-0.02
-26.32%
TSE:PREV
PreveCeutical Medical
0.02
-0.03
-60.00%
Hemostemix Corporate Events
Business Operations and StrategyPrivate Placements and FinancingProduct-Related AnnouncementsRegulatory Filings and Compliance
Hemostemix Wins Bahamas Approval for VesCell Trial and Advances Financing, Manufacturing
Positive
Oct 8, 2026
Hemostemix has secured full approval from The Bahamas’ National Longevity and Regenerative Therapy Board, including ethics clearance, to run a commercial Phase 1 study of its VesCell therapy for angina, vascular dementia and pain, strengthen...
Business Operations and StrategyPrivate Placements and Financing
Hemostemix Advances $1 Million Private Placement to Fund Stem Cell Therapy Commercialization
Positive
Sep 24, 2026
Hemostemix Inc. has moved to secure price protection as it prepares to close the third tranche of a previously announced non‑brokered private placement, aiming to raise $1 million through units comprising common shares and warrants listed on...
Business Operations and StrategyPrivate Placements and Financing
Hemostemix Raises CDN$322,250 in Second Tranche of Private Placement
Positive
Aug 6, 2026
Hemostemix Inc. has closed the second tranche of its non-brokered private placement, raising CDN$322,250 through the issuance of 6,445,000 units priced at CDN$0.05, each comprising a common share and half a warrant exercisable at CDN$0.12. The com...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.